Omega Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Omega Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-0.06%

Rückkaufsrendite

Gesamte Aktionärsrendite	-0.06%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M

Aug 04

Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002

Jul 14

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von OMGA in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von OMGA gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Omega Therapeutics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von OMGA im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (OMGA)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (OMGA) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von OMGA im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von OMGA im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von OMGA, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da OMGA keine Ausschüttungen gemeldet hat.

Omega Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Omega Therapeutics, Inc. Announces Chief Executive Officer Changes

High number of new directors

Omega Therapeutics, Inc. Elects Robert L. Rosiello as Class I Director

Omega Therapeutics, Inc. Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

Omega Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 30%

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell Small Cap Completeness Index

Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors

Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer

Consensus revenue estimates increase by 24%

Full year 2023 earnings released: US$1.80 loss per share (vs US$2.15 loss in FY 2022)

New major risk - Revenue and earnings growth

Omega Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control

Consensus revenue estimates increase by 43%

Price target decreased by 9.2% to US$11.20

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

Full year 2023 earnings released: US$1.80 loss per share (vs US$2.15 loss in FY 2022)

Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?

Omega Therapeutics: The Next Weight Loss Drug Runner

Omega Therapeutics: Starting 2024 With A Bang

Consensus revenue estimates increase by 26%

Omega Therapeutics, Inc. Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

New minor risk - Market cap size

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial

Price target increased by 8.6% to US$13.40

High number of new directors

Omega Therapeutics, Inc. Announces Board Changes

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Omega Therapeutics Appoints Chris Schade to Its Board of Directors

Price target decreased by 9.0% to US$11.83

Consensus EPS estimates upgraded to US$2.23 loss

Forecast to breakeven in 2025

Price target increased by 14% to US$14.80

Consensus revenue estimates increase by 57%

Board Member notifies of intention to sell stock

Forecast to breakeven in 2025

Price target decreased by 17% to US$13.00

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 62%

Price target increased to US$18.50

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma

Omega Therapeutics, Inc. Announces First Patient Dosed in Landmark MYCHELANGELO(TM) I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene

Omega Therapeutics, Inc. Unveils New Epigenomic Controller Development Candidate Targeting MYC Driven Non-Small Cell Lung Cancer

Omega Therapeutics, Inc. Announces Appointment of Rainer Boehm to its Board of Directors

Consensus forecasts updated

Price target increased to US$20.67

Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M

High number of new directors

Omega Therapeutics, Inc. Announces U.S. Food and Drug Administration Clearance of IND Application for OTX-2002

Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002

Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the First Epigenomic Controller, Otx-2002, as A Potential Therapeutic Approach in Hepatocellular Carcinoma At the Esmo 2022 World Congress on Gastrointestinal Cancer

Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from Russell 2500 Value Index

Omega Therapeutics, Inc. Announces Submission of Investigational New Drug Application for Otx-2002

Omega Therapeutics Announces Appoints Joshua Reed as Chief Financial Officer, Effective May 23, 2022

High number of new directors

Omega Therapeutics Inc. Announces Executive Changes

High number of new directors

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen